INTRODUCTION

Hypereosinophilic syndrome (HES) is a group of disorders marked by the sustained overproduction of eosinophils, in which eosinophilic infiltration and the release of mediators cause damage to multiple organs, including the skin, cardio-pulmonary region, and the gastrointestinal tract. HES is rare, and its true prevalence is unknown. In a study that used the clinical code of eosinophilia to identify patients with HES in the Surveillance, Epidemiology, and Final Results (SEER) database, the estimated prevalence was 0.36 per 100,000 individuals. Most patients are between 20 and 50 years of age at the time of diagnosis, although this condition can also be observed in children (1).

Eosinophilia can be considered mild, when the absolute eosinophil count (AEC) in peripheral blood is above the reference limit (AEC <1,500/mm$^3$), moderate (AEC between 1,500 and 5,000/mm$^3$), and severe (AEC >5,000/mm$^3$). Hypereosinophilia (HE) occurs when there is a moderate to severe increase in AEC (>1,500/mm$^3$ or >1,500 cells/µL) in two separate tests within at least one month and/or pathological confirmation of HE tissue (1-4). HES is characterized by the association of HE (as defined above) with damage and/or dysfunction mediated by eosinophils in organs, as long as other potential causes of the damage have been excluded (1).

The term “HES” can therefore be used to qualify any condition characterized by eosinophilic infiltrates and associated complications, including situations in which the cause of HE is identified (for example, restrictive heart disease occurring in the context of parasitic infections [Löffler’s endocarditis]). The categories of HES are further sub-classified according to the pathogenic mechanisms that result in the expansion of eosinophils: primary being the most described myeloproliferative variant in the literature, secondary (reactive) resulting from cytokines that stimulate eosinophilia, or idiopathic being a diagnosis of exclusion (1,4).

The goal of treatment for patients with HES is to reduce the long-term levels of eosinophils in the blood and tissues to reverse and prevent the damage to target organs. Except for patients with imatinib-sensitive HES variants, including those associated with FIP1 like-1 platelet-derived growth factor receptor. Mepolizumab (MEP) is a humanized monoclonal antibody that targets the high-affinity receptor for the eosinophil chemotaxin eotaxin-2 (Eotaxin-2) and Eotaxin-3 ( homelessness). The approved clinical indications for MEP are in the context of severe asthma and eosinophilic gastroenteritis (EG) (5). In both of these conditions, eosinophils are involved in tissue damage and/or dysfunction.

We aimed to evaluate the efficacy and safety of mepolizumab (MEP) in the management of hypereosinophilic syndrome (HES). A systematic search was performed, and articles published until March 2021 were analyzed. The primary efficacy results evaluated were hospitalization rate related to HES, morbidity (new or worsening), relapses/failure, treatment-related adverse effects, prednisone dosage and eosinophil count <600 µL/L for >8 weeks. A meta-analysis was conducted, when appropriate. Three randomized controlled trials (RCTs), with a total of 255 patients, were included. The studies contemplated the use of MEP 300 mg/SC or 750 mg/IV. According to the evaluation of the proposed outcomes, when relapse rates/therapeutic failures were assessed, there was a 26% reduction with MEP 300 mg/SC (RD=−0.26; 95% CI: −0.44 to −0.08; p=0.04) and 48% reduction with MEP 750 mg/IV (RD=−0.48; 95% CI: −0.67, −0.30; p<0.00001). For the outcomes, prednisone dosage ≤10 mg/day for >8 weeks was 48% (RD=0.48; 95% CI: 0.35 to 0.62; p<0.00001), and the eosinophil count <600 µL/L for >8 weeks was 51% (RD=0.51; 95% CI: 0.38 to 0.63; p<0.00001), both showed a reduction with MEP 300 mg/IV and 750 mg/IV. No statistically significant differences in treatment-related adverse effects outcomes were observed for either dosage (RD=0.09; 95% CI: −0.05 to 0.24; p=0.20; RD=0.09; 95% CI: −0.11 to 0.29; p=0.39). Despite the positive effects observed for the studied outcomes, the exact significance remains unclear.

KEYWORDS: Mepolizumab; Humanized Monoclonal Antibody; Hypereosinophilic Syndrome.

Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis

José Mario Alves Júnior, I,* Francisco Eduardo Prota, I Danilo Villagelin, I Fernanda Bley, II Wanderley Marques Bernardo, III, IV

1Unimed Campinas Cooperativa de Trabalho Medico – Gestao e Valor em Saude, Campinas, SP, BR. 2Emeneer Gestao em Saude – Medicina Baseada em Evidencia, Sao Paulo, SP, BR. 3Unimed Fesp – Fedecacao das Unimedos do Estado de Sao Paulo, Sao Paulo, SP, BR. 4Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.

Alves Júnior JM, Prota FE, Villagelin D, Bley F, Bernardo WM. Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis. Clinics (Sao Paulo). 2021;76:e3271

*Corresponding author. E-mail: jmalves@unimedcampinas.com.br

Copyright © 2021 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

No potential conflict of interest was reported.

Received for publication on June 29, 2021. Accepted for publication on August 26, 2021

DOI: 10.6061/clinics/2021/e3271
factor α-fusion gene (FIP1L1-PDGFRA), the standard of care is the administration of glucocorticoids and cytotoxic/immunosuppressive therapy. However, these drugs have variable efficacy and are often associated with significant morbidity and adverse side effects. The heterogeneous nature of the disease also makes clinical management challenging, with patients typically exhibiting different patterns of disease activity (for example, worsening or relapse of symptoms). Interleukin (IL)-5 is a key regulator of the biology of eosinophils, so therapy directed against the IL-5 pathway has been explored as a potential treatment strategy for patients with HES. Mepolizumab (MEP) is a humanized monoclonal antibody (IgG1, kappa) that acts on human IL-5 with high affinity and specificity (2,3).

**MATERIALS AND METHODS**

**Protocol and Registration**

The study protocol was registered in the International Prospective Registry of Systematic Reviews (PROSPERO) under the number CRD42021242338. Reporting for this review is in line with the recommendations of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.

**Eligibility Criteria**

Only those randomized controlled trials (RCTs) and observational studies with a control group, which were published or presented in summary form in English, Spanish, and Portuguese, were included; however, there was no limitation on the year of publication. Studies with the following characteristics were included: (i) Participants: Adult and pediatric patients with HES, fusion of the negative gene for FIP1L1–PDGFRA; (II) Intervention: Use of MEP at any dosage or route of administration; (III) Comparison: Other treatments, including placebo; (IV) Results: Hospitalization rate related to HES, morbidity (new or worsening), relapse/failure, adverse effects related to treatment, prednisone dosage ≤10 mg/day for ≥8 weeks, and eosinophil count <600/μL per ≥8 weeks. The exclusion criteria were as follows: (I) Studies using non-humans and (II) fusion of the positive gene for FIP1L1–PDGFRA.

**Research and Study Selection**

The research was exclusively carried out using electronic databases [Medline (https://pubmed.ncbi.nlm.nih.gov/), Cochrane Library (https://www.cochranelibrary.com/), and Lilacs/Bireme (https://lilacs.bvsalud.org/)] from the beginning until March 2021. The sensitive research strategy for the databases consulted was: (Hypereosinophilic Syndrome OR Hypereosinophilic Syndromes OR Eosinophilic Leukemia OR Eosinophilic Leukemias OR Loeffler’s Endocarditis OR Loefflers Endocarditis OR Loeffler Endocarditis OR Idiopathic Hypereosinophilic Syndrome OR Idiopathic Hypereosinophilic Syndromes OR Pulmonary Eosinophilia) AND (MEP OR Bosatria OR SB240563 OR Nucala). Two independent researchers screened for eligibility. Any disagreements were resolved by consensus or consultation with a third reviewer.

**Data Collection Process**

Two independent reviewers extracted and organized the relevant data in the form of tables. The primary results were prednisone dosage ≤10 mg/day for ≥8 weeks and eosinophil count <600/μL for ≥8 weeks. Secondary results were as follows: Hospitalization rate related to HES, morbidity (new or worsening), relapses/failure, and adverse effects related to treatment.

**Risk of Bias in Individual Studies**

The selected evidence was defined as a RCT and submitted to an appropriate critical assessment checklist, covering the following items: randomization, blindfolded allocation, double-blinding, evaluator binding, losses (<20%), characteristic prognoses, appropriate outcomes, ITT analysis, sample calculation, and early interruption.

**Measures, Summary of Results, and Quality of Evidence**

Based on the results of discrete quantitative variables, the differences between their measurements were calculated using the absolute number of events, as well as the sample size of each group. Statistical analyses were performed using the Review Software manager, v.5.4 (RevMan 5.4; Cochrane Collaboration, Oxford, UK), using the risk difference (RD). A 95% confidence interval was adopted, and the level of statistical significance was established with a p-value of less than 0.05. Meta-analyses were performed using the fixed-effects model, as they did not show >50% heterogeneity. The results of each outcome were graphically analyzed using forest plots. The quality of evidence was analyzed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) classification.

**RESULTS**

**Study Selection**

The study selection process adopted, which identified 230 citations in the databases consulted, is demonstrated in Figure 1, and the characteristics of the included studies are summarized in Table 1.

All studies identified were evaluated by title/abstract, and nine studies were selected for full-text review. Of these, three studies had no control group, two were summaries related to an included RCT, and one had not yet been published on the current date. After exclusion, this review included one individual study that was not subjected to meta-analysis and two studies whose characteristics and outcomes could be meta-analyzed.

**Risk of Bias in Studies**

In general, the included RCTs had a low risk of bias, as shown in Table 2.

**Results of Individual Studies**

The results of the individual studies are summarized in Table 3.

**SUMMARY OF RESULTS**

**Relapse/Therapeutic Failure**

This outcome was evaluated in two different studies according to the dosage and route of administration of MEP. A study (2) with 108 patients used MEP 300 mg/SC (n=54) and the placebo control group (n=54). For this dosage, it was observed that in the MEP group, there was a 26% reduction in the number of relapses (RD=-0.26; 95% CI: -0.44, -0.08; p=0.004) (Figure 2). In another study (3) with 85 patients, 43 patients received MEP at a dosage of 750 mg/IV and 42 patients received the placebo, and the results showed that, in the MEP group, there was a 48% reduction in therapeutic
failure (RD=-0.48; 95% CI: -0.67 to -0.30; p<0.00001) (Figure 3).

**Treatment-Related Adverse Effects**

Similar to the previous outcome, the same studies (2,3) measured the results for this outcome according to the dosage and route of administration. Regardless of the dosage of 300 mg/SC or 750 mg/IV, no statistically significant differences were observed: RD=0.09; 95% CI: -0.05 to 0.24; p=0.20 and RD=0.09; 95% CI: -0.11 to 0.29; p=0.39, respectively (Figures 4 and 5).

**Prednisone Dosage ≤ 10 mg/day for ≥8 weeks**

The decrease in the prednisone dosage in patients considered stable can be measured through the meta-analysis of two studies (3,5) involving 147 patients, of which, 74 patients received MEP at a dosage of 750 mg/IV and 73 patients in the control group received the placebo. The results of the meta-analysis showed that MEP reduces prednisone dosage by up to 48% to ≤10 mg/day for ≥8 weeks (Result: RD=0.48; 95% CI: 0.35 to 0.62; p<0.00001) (Figure 6).

**Eosinophil Count < 600/µL for ≥8 weeks**

Similar to the previous outcome, the same studies (3,5) also evaluated the decrease in circulating eosinophils in stable patients. In this case, the meta-analysis showed a 51% reduction in the eosinophil count to <600/µL for ≥8 weeks (RD=0.51; 95% CI: 0.38 to 0.63; p<0.00001) (Figure 7).

These outcomes provide a moderate degree of evidence according to the GRADE Working Group (Table 4).
Table 1 - Characteristics of the studies included in the meta-analysis.

| STUDIES                  | DESIGN | POPULATION                                                                 | INTERVENTION   | CONTROL | OUTCOMES                                           | FOLLOW-UP TIME |
|--------------------------|--------|-----------------------------------------------------------------------------|----------------|---------|----------------------------------------------------|----------------|
| Roufosse et al. 2020 (2) | RCT    | Patients $\geq$ 12, negative diagnosis of FIP1L1-PDGFR, uncontrolled HES (AEC $\geq$ 1000 cell/μL or $\geq$ 2 relapses in the last 12 months) and who were receiving previous therapy. (n=108) | MEP 300 mg/SC  (n=54) | Placebo  (n=54) | Relapses/failure and treatment-related adverse events | 32 weeks       |
| Roufosse et al. 2010 (5) | RCT    | Patients $\geq$ 18 years old with a diagnosis of HES, stable (prednisone 20–60 mg/day), with no new clinical sign or worsening, negative diagnosis of FIP1L1-PDGFR and AEC $\leq$ 1000 cell/μL (n=62) | MEP 750 mg/IV  (n=31) | Placebo  (n=31) | Prednisone dosage $\leq$ 10 mg/day for $\geq$ 8 weeks and eosinophil count $<600/μL$ for $\geq$ 8 weeks | 36 weeks       |
| Rothenberg et al. 2008 (3) | RCT    | Patients $\geq$ 18 years old with a diagnosis of HES, stable (prednisone 20–60 mg/day), without new clinical sign or worsening, negative diagnosis of FIP1L1-PDGFR and AEC $\leq$ 1000 cell/μL. (n=85) | MEP 750 mg/IV  (n=43) | Placebo  (n=42) | Prednisone dosage $\leq$ 10 mg/day for $\geq$ 8 weeks, eosinophil count $<600/μL$ for $\geq$ 8 weeks, relapse/failure rate | 36 weeks       |

Table 2 - Global risk of bias in each study.

| STUDIES                  | RANDOMIZATION | BLINDFOLDED ALLOCATION | DOUBLE BLINDING | EVALUATOR BLINDING | LOSSES ($\leq$ 20%) | PROGNOSTIC CHARACTERISTICS | APPROPRIATE OUTCOMES | ITT ANALYSIS | SAMPLE CALCULATION | EARLY INTERRUPTION |
|--------------------------|---------------|-------------------------|-----------------|-------------------|----------------------|---------------------------|-----------------------|--------------|-------------------|-------------------|
| Roufosse et al. 2020 (2) |               |                         |                 |                   |                      |                           |                       |              |                   |                   |
| Roufosse et al. 2010 (5) |               |                         |                 |                   |                      |                           |                       |              |                   |                   |
| Rothenberg et al. 2008 (3)|               |                         |                 |                   |                      |                           |                       |              |                   |                   |
Figure 2 - Forest plot reporting the decrease in therapeutic relapse.

Figure 3 - Forest plot reporting the decrease in therapeutic failure.

Figure 4 - Forest plot study reporting the adverse effects of mepolizumab (MEP) (300 mg/SC).

Figure 5 - Forest plot reporting the adverse effects of MEP (750 mg/IV).

Figure 6 - Forest plot reporting the decrease in prednisone dosage.

Figure 7 - Forest plot reporting the decrease in eosinophil count.
Table 3 - Summary of results according to the outcome of each study.

| STUDIES                     | Related hospitalization rate | New morbidity/worsening | Relapses that require therapeutic change | Adverse effects related to the agent | Prednisone dosage ≤10 mg/day for ≥ 8 weeks | Eosinophil count <600/μL for ≥ 8 weeks |
|-----------------------------|------------------------------|-------------------------|------------------------------------------|--------------------------------------|--------------------------------------------|------------------------------------------|
| MEP CONTROL                 | MEP CONTROL                  | MEP CONTROL             | MEP CONTROL                              | MEP CONTROL                          | MEP CONTROL                                | MEP CONTROL                              |
| Roufosse et al. 2020 (2)    | 14 de 54 (26%)               | 28 de 54 (52%)          | 12 de 54 (22%)                           | 7 de 54 (13%)                        | 29 de 31 (93.5%)                             | 30 de 31 (97%)                            |
| Roufosse et al. 2010 (5)    |                              |                        |                                          |                                      | 11 de 31 (35.5%)                             | 14 de 31 (45%)                            |
| Rothenberg et al. 2018 (3)  | 9 de 43 (21%)                | 29 de 42 (69%)          | 16 de 43 (37%)                           | 12 de 42 (29%)                       | 36 de 43 (84%)                               | 41 de 43 (95%)                            |

Table 4 - Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evaluation.

| Certainty assessment | No. of patients | Effect | Mepolizumab 750 mg/I | Placebo | Relative (95% CI) | Absolute (95% CI) | Certainty | Importance |
|----------------------|-----------------|--------|-----------------------|---------|-------------------|-------------------|-----------|------------|
| Prednisone dosage ≤10 mg/day for ≥ 8 weeks | 2 randomized clinical trials | 59/67 (88.1%) | 28/67 (41.8%) | not estimable | 460 less per 1,000 (from 600 less to 320 less) | MODERATE | |
| Eosinophil count <600/μL for ≥ 8 weeks | 2 randomized clinical trials | 65/67 (97.0%) | 32/67 (47.8%) | not estimable | 490 less per 1,000 (from 620 less to 360 less) | MODERATE | |

Explanations
CI: Confidence interval.
a. Losses > 20%.
**DISCUSSION**

MEP inhibits the binding of IL-5 to the α chain of the IL-5 receptor expressed in eosinophils, which allows its use in HES, more specifically in secondary and lymphocytic cells. These syndromes are associated with excessive production of cytokines, such as IL-3, IL-5, and the macrophage granulocyte colony-stimulating factor (GM-CSF), which in turn promote the maturation and survival of eosinophils, while inhibiting their apoptosis. IL-5 is the most important factor for this process; however, its binding and action can be inhibited by the use of anti-IL-5 to reduce eosinophilia (6).

Unlike MEP for the management of HES, large studies are available for patients with severe eosinophilic asthma, including RCTs and systematic reviews (7-15). For HES, there are still not many studies, mainly RCTs. Most studies that we found were reports and case series, which do not allow an in-depth assessment of the topic. Despite this review strictly following the criteria imposed by the PRISMA statement and selecting studies with adequate methodological quality, it was not possible to eliminate some limitations. The included studies had a small number of patients and generally belonged to the same group of authors. In addition, the studies used different inclusion criteria, dosages, and routes of administration, making it difficult to carry out a meta-analysis. Perhaps a large part of these limitations is inherent to the low prevalence of the disease, as well as the criteria for accurate diagnosis.

The other outcomes listed as secondary (hospitalization rate and morbidity) were not suitable for synthesis. The only study available that categorically assessed these outcomes has been published in the manuscript form (16).

The use of MEP as a treatment for hypereosinophilic syndrome is an extremely relevant issue for immunology, especially when there is an excessive increase in cytokines causing eosinophilia. In addition, it presents a possible therapeutic hope with anti-IL-5, which, compared to placebo, decreased the eosinophil count in controlled patients.

This systematic review reveals a scarcity of studies with adequate scientific rigor, especially RCTs. This scarcity prevents an adequate assessment of the use of MEP at different dosages and routes of administration for the treatment of HES, both for the uncontrolled and clinically controlled patients. However, MEP, when compared to placebo, seems to be superior for the following outcomes: decreased therapeutic failure, prednisone dose, and eosinophil count in controlled patients.

Due to the present lack of evidence, it is not yet possible to draw definitive conclusions about the significance of its use.

**CONCLUSION**

Despite the positive effects observed regarding the decrease in the prednisone dosage and eosinophil count in controlled patients as well as the decrease in relapses/therapeutic failures, these results should be interpreted with caution. The lack of robust evidence inherent in the available studies creates ambiguity regarding the significance of this benefit.

**AUTHOR CONTRIBUTIONS**

Alves Junior JM made considerable contributions to the design and postulation of the study, the definition of technical content, literature search, data analysis, statistical analysis, manuscript preparation, drafting, writing, critical review, and approval of the manuscript final version for publication. Prota FE and Villaglin D were involved in the data analysis, statistical analysis, manuscript preparation, writing, drafting, critical review for important intellectual content, and approval of the manuscript final version for publication. Bernardo WM and Bley F provided support for the entire process of developing and reviewing this systematic review.

**REFERENCES**

1. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contempory consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.e9. https://doi.org/10.1016/j.jaci.2012.02.019
2. Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397-405. https://doi.org/10.1016/j.jaci.2020.08.037
3. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;359(12):1215-28. https://doi.org/10.1056/NEJMo070612
4. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(10):1149-67. https://doi.org/10.1002/ajh.25617
5. Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(4):828-835.e3. https://doi.org/10.1016/j.jaci.2010.06.049
6. Stella S, Massimino M, Manzella L, Pennisi MS, Tirro E, Romano C, et al. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes. Int J Mol Sci. 2021;22(23):486. https://doi.org/10.3390/ijms2223486
7. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97. https://doi.org/10.1056/NEJMo1403291
8. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhi R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled, parallel-group trial. Lancet. 2012;380(9842):651-9. https://doi.org/10.1016/S0140-6736(12)60988-X
9. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-84. https://doi.org/10.1056/NEJMo0808991
10. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with spu- tum eosinophilia. N Engl J Med. 2009;360(10):985-93. https://doi.org/10.1056/NEJMo0805345
11. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207. https://doi.org/10.1056/NEJMo1403290
12. Castro M, Mathur S, Hargrave E, Boulter LP, Xie F, Young J, et al. Resli- zumab for poorly controlled eosinophilic asthma: a randomized, placebo- controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-32. https://doi.org/10.1164/rccm.201103-0396OC
13. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nielsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400. https://doi.org/10.1016/S2213-2600(17)30125-X
14. Yancey SW, Ortega HG, Keene ON, Mayer B, Gunsoy NB, Brightling CE, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2017;139(4):1167-1175.e2. https://doi.org/10.1016/j.jaci.2016.08.028
15. Agache I, Beltran J, Ajdik C, Ajdik M, Caneio-Aybar C, Canonicow GA, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosi- nophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-42. https://doi.org/10.1111/all.14221
16. Kuang FL, Fay MP, Ware J, Wetzel L, Holland-Thomas N, Brown T, et al. Long-term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. J Allergy Clin Immunol Pract. 2018;6(5):1518-1527.e5. https://doi.org/10.1016/j.jaip.2018.04.033